On June 11, M2D2 Resident Company Glyscend Therapeutics announced the closing of a Series A financing round valued at $20.5 million. Glyscend will use this funding to further support the development of its novel oral polymer therapy for patients with type 2 diabetes, as well as other metabolic diseases.
Continue readingDuring the second week of June, two M2D2 resident companies took part in this year’s BIO Digital Convention. LivOnyx Inc. and Versatope Therapeutics both presented their progress and innovative solutions during BIO Digital Week, a virtual convention featuring interactive sessions covering therapeutics, digital health, patient advocacy, and more. Both of these startups are working on solutions that are very relevant during the COVID-19 pandemic.
Continue reading
M2D2 Resident Company Versatope and Netherlands-based Intravacc announced on June 8th, that they have signed a research service agreement to further develop a universal vaccine against influenza. The vaccine will be based on Intravacc’s innovative Outer Membrane Vesicles (OMV) technology, which is proven to be safe in humans.
Continue readingWe are always excited to share the news about our resident companies’ successes. Tuesday morning, LaunchPad Medical announced that they received support up to $1.8 million from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center. It was funded by the National Institute of Dental and Cranial Research to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice.
Continue reading